For the year ending 2025-12-31, EMMA made $12,453K in revenue. -$7,226K in net income. Net profit margin of -58.03%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenues, net | 12,453 | |||
| Cost of goods sold | 857 | |||
| Gross profit | 11,596 | |||
| Research and development | 313 | |||
| Selling | 2,873 | |||
| General and administrative | 8,179 | |||
| Total operating expenses | 11,365 | |||
| Income (loss) from operations | 231 | |||
| Debt extinguishment | -1,363 | |||
| Change in fair value of warrant derivative liabilities | -5 | |||
| Change in fair value of conversion feature derivative, notes payable | 162 | |||
| Realized loss on investment in convertible bond | -531 | |||
| Gain (loss) on lease modification | 861 | |||
| Foreign exchange loss | 26 | |||
| Interest and other income (net) | 270 | |||
| Interest expense | 7,134 | |||
| Total other expense | -7,714 | |||
| Loss before income taxes | -7,483 | |||
| Income tax provision | 9 | |||
| Net loss | -7,492 | |||
| Unrealized gain (loss) on debt securities available for sale (net of tax) | -84 | |||
| Reclassification adjustment for loss included in net loss | 354 | |||
| Foreign currency translation adjustments | -4 | |||
| Other comprehensive income (loss) | 266 | |||
| Comprehensive loss | -7,226 | |||
| Basic EPS | -0.12 | |||
| Diluted EPS | -0.12 | |||
| Basic Average Shares | 64,038,795 | |||
| Diluted Average Shares | 64,038,795 | |||
Emmaus Life Sciences, Inc. (EMMA)
Emmaus Life Sciences, Inc. (EMMA)